{"name":"Alkermes plc","slug":"alkermes","ticker":"ALKS","exchange":"NASDAQ","domain":"alkermes.com","description":"Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio.","hq":"Dublin, Ireland","founded":0,"employees":"2050","ceo":"Richard Pops","sector":"Specialty Pharma","stockPrice":34.18,"stockChange":1.16,"stockChangePercent":3.51,"marketCap":"$5.7B","metrics":{"revenue":1720000000,"revenueGrowth":-10.6,"grossMargin":86.7,"rdSpend":323964000,"netIncome":241664000,"cash":588214976,"dividendYield":0,"peRatio":24.6,"fiscalYear":"FY2025"},"revenueBreakdown":[{"name":"Aristada","genericName":"ARIPIPRAZOLE LAUROXIL","slug":"aripiprazole-lauroxil","revenue":500000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"2015-01-01","label":"Aristada first approved","drug":"Aristada","drugSlug":"aripiprazole-lauroxil","type":"approval","sentiment":"positive"},{"date":"2021-01-01","label":"Lybalvi first approved","drug":"Lybalvi","drugSlug":"samidorphan","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2032-03-19","label":"Aristada patent expiry (Method of Use)","drug":"Aristada","drugSlug":"aripiprazole-lauroxil","type":"patent_expiry","sentiment":"negative"},{"date":"2032-11-07","label":"Aristada patent expiry (Formulation)","drug":"Aristada","drugSlug":"aripiprazole-lauroxil","type":"patent_expiry","sentiment":"negative"},{"date":"2033-09-19","label":"Aristada patent expiry (Formulation)","drug":"Aristada","drugSlug":"aripiprazole-lauroxil","type":"patent_expiry","sentiment":"negative"},{"date":"2033-10-24","label":"Aristada patent expiry (Formulation)","drug":"Aristada","drugSlug":"aripiprazole-lauroxil","type":"patent_expiry","sentiment":"negative"},{"date":"2033-10-24","label":"Aristada patent expiry (Formulation)","drug":"Aristada","drugSlug":"aripiprazole-lauroxil","type":"patent_expiry","sentiment":"negative"},{"date":"2033-10-24","label":"Aristada patent expiry (Formulation)","drug":"Aristada","drugSlug":"aripiprazole-lauroxil","type":"patent_expiry","sentiment":"negative"},{"date":"2035-03-19","label":"Aristada patent expiry (Method of Use)","drug":"Aristada","drugSlug":"aripiprazole-lauroxil","type":"patent_expiry","sentiment":"negative"},{"date":"2035-03-19","label":"Aristada patent expiry (Method of Use)","drug":"Aristada","drugSlug":"aripiprazole-lauroxil","type":"patent_expiry","sentiment":"negative"},{"date":"2035-03-19","label":"Aristada patent expiry (Method of Use)","drug":"Aristada","drugSlug":"aripiprazole-lauroxil","type":"patent_expiry","sentiment":"negative"},{"date":"2035-03-19","label":"Aristada patent expiry (Method of Use)","drug":"Aristada","drugSlug":"aripiprazole-lauroxil","type":"patent_expiry","sentiment":"negative"},{"date":"2035-03-19","label":"Aristada patent expiry (Formulation)","drug":"Aristada","drugSlug":"aripiprazole-lauroxil","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"VIVITROL patent cliff ($444.4M at risk)","drug":"VIVITROL","type":"patent_expiry","sentiment":"negative"},{"date":"2034-06-01","label":"CARIPrazine patent cliff ($143.8M at risk)","drug":"CARIPrazine","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":500000000,"percentOfTotal":100,"drugCount":9,"colorKey":"oncology","drugs":[{"name":"Aristada","genericName":"ARIPIPRAZOLE LAUROXIL","slug":"aripiprazole-lauroxil","indication":"Schizophrenia","status":"marketed","revenue":500000000},{"name":"High Dose ALKS 5461","genericName":"High Dose ALKS 5461","slug":"high-dose-alks-5461","indication":"Major depressive disorder (Phase 3)","status":"phase_3"},{"name":"OLZ/SAM","genericName":"OLZ/SAM","slug":"olz-sam","indication":"Treatment of schizophrenia","status":"phase_3"},{"name":"ALK3831","genericName":"ALK3831","slug":"alk3831","indication":"Schizophrenia (maintenance treatment)","status":"phase_3"},{"name":"ALKS 2680 Dose 1","genericName":"ALKS 2680 Dose 1","slug":"alks-2680-dose-1","indication":"Cognitive impairment associated with schizophrenia","status":"phase_3"},{"name":"ALKS 37","genericName":"ALKS 37","slug":"alks-37","indication":"Treatment-resistant schizophrenia","status":"phase_2"},{"name":"Baclofen ER","genericName":"Baclofen ER","slug":"baclofen-er","indication":"Spasticity associated with multiple sclerosis","status":"marketed"},{"name":"LYBALVI","genericName":"LYBALVI","slug":"lybalvi","indication":"Schizophrenia","status":"marketed"},{"name":"Lybalvi","genericName":"SAMIDORPHAN","slug":"samidorphan","indication":"Schizophrenia","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"immunology","drugs":[{"name":"ALKS 33-BUP","genericName":"ALKS 33-BUP","slug":"alks-33-bup","indication":"Other","status":"phase_1"},{"name":"Motrin","genericName":"Motrin","slug":"motrin","indication":"Other","status":"marketed"},{"name":"ALKS 33","genericName":"ALKS 33","slug":"alks-33","indication":"Other","status":"phase_1"},{"name":"ALKS 3831","genericName":"ALKS 3831","slug":"alks-3831","indication":"Other","status":"phase_3"},{"name":"ALKS 9072, Med dose","genericName":"ALKS 9072, Med dose","slug":"alks-9072-med-dose","indication":"Other","status":"phase_1"},{"name":"NTX/PBO-B","genericName":"NTX/PBO-B","slug":"ntx-pbo-b","indication":"Chronic weight management in obese or overweight adults with weight-related comorbidities","status":"phase_3"},{"name":"VIVITROL 380mg","genericName":"VIVITROL 380mg","slug":"vivitrol-380mg","indication":"Other","status":"marketed"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"cardiovascular","drugs":[{"name":"ALKS 9072","genericName":"ALKS 9072","slug":"alks-9072","indication":"Moderate to severe acute pain","status":"phase_3"},{"name":"ALKS 9072, High","genericName":"ALKS 9072, High","slug":"alks-9072-high","indication":"Moderate to severe acute pain","status":"phase_3"},{"name":"ALKS 9072, Low","genericName":"ALKS 9072, Low","slug":"alks-9072-low","indication":"Opioid use disorder","status":"phase_3"},{"name":"Low Dose ALKS 5461","genericName":"Low Dose ALKS 5461","slug":"low-dose-alks-5461","indication":"Moderate to severe acute pain","status":"phase_3"},{"name":"NTX/BUP","genericName":"NTX/BUP","slug":"ntx-bup","indication":"Opioid use disorder (maintenance treatment)","status":"phase_3"},{"name":"PBO-N/PBO-B","genericName":"PBO-N/PBO-B","slug":"pbo-n-pbo-b","indication":"Moderate to severe pain","status":"phase_3"}]}],"pipeline":[{"name":"Aristada","genericName":"ARIPIPRAZOLE LAUROXIL","slug":"aripiprazole-lauroxil","phase":"marketed","mechanism":"Aristada works by blocking dopamine receptors in the brain to help regulate abnormal thought and behavior patterns.","indications":["Schizophrenia"],"catalyst":""},{"name":"ALKS 33-BUP","genericName":"ALKS 33-BUP","slug":"alks-33-bup","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"High Dose ALKS 5461","genericName":"High Dose ALKS 5461","slug":"high-dose-alks-5461","phase":"phase_3","mechanism":"ALKS 5461 is a combination of buprenorphine and samidorphan that acts as a partial mu-opioid receptor agonist while blocking opioid-induced side effects through antagonism at the opioid receptor.","indications":["Major depressive disorder (Phase 3)","Opioid use disorder (earlier development stage)"],"catalyst":""},{"name":"Motrin","genericName":"Motrin","slug":"motrin","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"OLZ/SAM","genericName":"OLZ/SAM","slug":"olz-sam","phase":"phase_3","mechanism":"OLZ/SAM is an oral, fixed-dose combination of olanzapine and samidorphan, a partial agonist at the μ-opioid receptor.","indications":["Treatment of schizophrenia"],"catalyst":""},{"name":"ALK3831","genericName":"ALK3831","slug":"alk3831","phase":"phase_3","mechanism":"ALK3831 is a long-acting injectable formulation of aripiprazole designed to provide sustained dopamine D2/D3 receptor antagonism for antipsychotic effect.","indications":["Schizophrenia (maintenance treatment)","Bipolar I disorder (maintenance treatment)"],"catalyst":""},{"name":"ALKS 2680 Dose 1","genericName":"ALKS 2680 Dose 1","slug":"alks-2680-dose-1","phase":"phase_3","mechanism":"ALKS 2680 is a muscarinic M1 receptor partial agonist designed to enhance cognitive function and treat psychiatric symptoms.","indications":["Cognitive impairment associated with schizophrenia","Negative symptoms of schizophrenia"],"catalyst":""},{"name":"ALKS 33","genericName":"ALKS 33","slug":"alks-33","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALKS 37","genericName":"ALKS 37","slug":"alks-37","phase":"phase_2","mechanism":"ALKS 37 is a dual GABA_A receptor agonist.","indications":["Treatment-resistant schizophrenia"],"catalyst":""},{"name":"ALKS 3831","genericName":"ALKS 3831","slug":"alks-3831","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALKS 9072","genericName":"ALKS 9072","slug":"alks-9072","phase":"phase_3","mechanism":"ALKS 9072 is a mu opioid receptor agonist combined with an opioid antagonist designed to provide analgesia while reducing abuse potential.","indications":["Moderate to severe acute pain"],"catalyst":""},{"name":"ALKS 9072, High","genericName":"ALKS 9072, High","slug":"alks-9072-high","phase":"phase_3","mechanism":"ALKS 9072 is a mu opioid receptor agonist combined with an opioid antagonist designed to provide analgesia while reducing abuse potential.","indications":["Moderate to severe acute pain"],"catalyst":""},{"name":"ALKS 9072, Low","genericName":"ALKS 9072, Low","slug":"alks-9072-low","phase":"phase_3","mechanism":"ALKS 9072 is a mu opioid receptor partial agonist designed to treat opioid use disorder by reducing cravings and withdrawal symptoms.","indications":["Opioid use disorder"],"catalyst":""},{"name":"ALKS 9072, Med dose","genericName":"ALKS 9072, Med dose","slug":"alks-9072-med-dose","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Baclofen ER","genericName":"Baclofen ER","slug":"baclofen-er","phase":"marketed","mechanism":"Baclofen ER is a GABA-B receptor agonist that reduces neuronal excitability and muscle tone by enhancing inhibitory neurotransmission in the central nervous system.","indications":["Spasticity associated with multiple sclerosis","Spasticity resulting from spinal cord injury or disease","Muscle spasticity of other origins"],"catalyst":""},{"name":"LYBALVI","genericName":"LYBALVI","slug":"lybalvi","phase":"marketed","mechanism":"LYBALVI is a combination of lurasidone (an atypical antipsychotic) and samidorphan (an opioid antagonist) that blocks dopamine and serotonin receptors while antagonizing opioid receptors to reduce antipsychotic-induced weight gain.","indications":["Schizophrenia","Bipolar I disorder (acute manic or mixed episodes)"],"catalyst":""},{"name":"Low Dose ALKS 5461","genericName":"Low Dose ALKS 5461","slug":"low-dose-alks-5461","phase":"phase_3","mechanism":"ALKS 5461 is a combination of buprenorphine and samidorphan that acts as a partial mu-opioid receptor agonist while blocking opioid-induced side effects through opioid antagonism.","indications":["Moderate to severe acute pain","Chronic pain management"],"catalyst":""},{"name":"Lybalvi","genericName":"SAMIDORPHAN","slug":"samidorphan","phase":"marketed","mechanism":"Lybalvi blocks the action of opioids at their receptor sites in the brain.","indications":["Schizophrenia","Bipolar I Disorder - Acute Manic or Mixed Episodes","Bipolar I Disorder - Maintenance Monotherapy"],"catalyst":""},{"name":"NTX/BUP","genericName":"NTX/BUP","slug":"ntx-bup","phase":"phase_3","mechanism":"NTX/BUP is a fixed-dose combination of naltrexone (an opioid antagonist) and buprenorphine (a partial opioid agonist) that reduces opioid cravings and withdrawal symptoms while blocking euphoric effects of additional opioid use.","indications":["Opioid use disorder (maintenance treatment)"],"catalyst":""},{"name":"NTX/PBO-B","genericName":"NTX/PBO-B","slug":"ntx-pbo-b","phase":"phase_3","mechanism":"NTX/PBO-B is a combination of naltrexone (an opioid antagonist) and bupropion (an antidepressant) designed to reduce appetite and promote weight loss.","indications":["Chronic weight management in obese or overweight adults with weight-related comorbidities"],"catalyst":""},{"name":"PBO-N/PBO-B","genericName":"PBO-N/PBO-B","slug":"pbo-n-pbo-b","phase":"phase_3","mechanism":"PBO-N/PBO-B is a partial opioid agonist.","indications":["Moderate to severe pain"],"catalyst":""},{"name":"VIVITROL 380mg","genericName":"VIVITROL 380mg","slug":"vivitrol-380mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Alkermes Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Alkermes reported fourth quarter and full year 2023 financial results, with net sales of $444.4 million and $1.7 billion, respectively.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Alkermes Announces Collaboration with Biogen to Develop and Commercialize ALKS 6100","summary":"Alkermes entered into a collaboration with Biogen to develop and commercialize ALKS 6100, a potential treatment for multiple sclerosis.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"Alkermes Receives FDA Approval for VIVITROL for the Treatment of Opioid Use Disorder","summary":"Alkermes received FDA approval for VIVITROL for the treatment of opioid use disorder.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5YdVRNRFBydThIQkQ2QmtNcjFnQkdIZmdIUWdNNU5vXzJBUlN2VWVlUkZFZ282YVdWM0tsNXliVGlHSmFQaGJUdzQxSFdEMFdWMEhIdEo2MHBDX0xPcWMwT2ttUmFaSUgyNk96T0xn?oc=5","date":"2026-03-21","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Alkermes Plc (ALKS) - Stock Titan","headline":"If You Invested $1,000 in Alkermes Plc (ALKS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxPTVlTSmFyOXp4UFJ0ZTBta3ZMeFlzU1dlNDhycEV2YmJ1Z2haV3lMT1JtSmsxV3pCdG9CSV9BaFcxV001ckx4ajNqbDk3ZFNzODBfb3BEd2ZxZTFKMHFWNW9uMEpPWlNZYjFwTFFqS0syUElWZVNTR3lGZHRhRnZucjlrTDI?oc=5","date":"2026-02-16","type":"deal","source":"Arthur Cox LLP","summary":"Avadel Pharmaceuticals plc acquired by Alkermes plc - Arthur Cox LLP","headline":"Avadel Pharmaceuticals plc acquired by Alkermes plc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQR3dIbFlMREhXQnhvaE1BTVZnX2xJTkVrbktUY3I5YUM5NFpBcGVCcHFFWEZCLXFZNDdPb291bHNqRnQ1bjFEOS1NeGpuY2VVd0tBTFpETS04VnNpMDRYeWs2bnc3RnVPNjVuSkU3ZXBmR0tnUHBaQmtLWC1kdmNXT3lYZWxianlHWW9id0R4M3l1M0FSRGVrWTJtRUZxMFRlYmJQeHZQMHQ0WTA5TzNRdzVub3JOamtYeS1JOG0ya0U?oc=5","date":"2026-02-16","type":"deal","source":"ALCHEMPro","summary":"Ireland's Alkermes plc buys Avadel Pharmaceuticals plc - ALCHEMPro","headline":"Ireland's Alkermes plc buys Avadel Pharmaceuticals plc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxONG13TU1YZkd5MDRiVy12YUZmVG5vY0p6UktRTUF5M1BuWHVNTTZVeFZrb0FERi1fT2dWX1ZxVzFicTRLMHdSVTlPTDV6dTcyaU4tU3laZ3F6WXYxTk1PTHFzQ1kzZXBBM2NzWTdRTzFhQ0hCMTZQSWVaX1U2dFMzbnppRmtMdndkUm1NaGtYdWRMX2s0U09uZlZ2QTJVYWg4WEU0UkNaLWMwWXU1ZURzV2dhOE5rQQ?oc=5","date":"2026-02-12","type":"deal","source":"Stock Titan","summary":"Alkermes (Nasdaq: ALKS) closes Avadel (Nasdaq: AVDL) buyout with cash and CVRs - Stock Titan","headline":"Alkermes (Nasdaq: ALKS) closes Avadel (Nasdaq: AVDL) buyout with cash and CVRs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPTE50NHhDdWItSU1pd29QSjl2dkYyaU9JZ01xai1lc3VJQ2w1dl9mSkVDekJ1dXJmRjlLdFdRa0lCZkhJSVViQnFlOVRiSTZEZG5IZ2VRNlpGTmJnbmlJRXNQRU9ZLUUxS0RtazR6eGdxLU4ycUpVREs1QnJEOWFjTnlqaW13S3dnQW1HZXVib3pYMHAxWlFmR09OcmY5MWItZnAxaGdlZEpfQU5xaUlsa3JvcFFlMGNa?oc=5","date":"2026-01-15","type":"regulatory","source":"The Business Journals","summary":"Avadel Pharmaceuticals shareholders approve $2.37B takeover bid - The Business Journals","headline":"Avadel Pharmaceuticals shareholders approve $2.37B takeover bid","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNSHh4WHJQcUU4LWZQdmNMdklVYlNzU2h5RVluYmpaMGFxR29jaV9vdGh4cHZtcHNTV2ozNzMwOTFqeDlBY2E0SDVVdFlBaG1HZ3NzMWpUN252QkhIT0pxMEFob0h4d2s3M3ZJSXc0QkJVdE9wM3BucDFaQk5uU1d3S0ZYYi1RQ3g2UGNoOXJndm5tbHNJYm1hdDdja3BfZUM2X2c?oc=5","date":"2025-11-20","type":"deal","source":"Finviz","summary":"ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal - Finviz","headline":"ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxQLS1rQS1ZLWRHZEE1WWdBTEpWdWlUWDF4MTA5ZzVqZ09SV01hdnZ1OEZWV0xiSEVSLTY2eWU0MjBfdzJNOVRWVWpXamFHUzYzTkNpYm5HamM5SnJNYkZ3Szdmby01UWZVek12TFg0X04xM2ZXcDhkc3NidnpnbWFqUnplM3JiVGRMbzVZV0tDbG5ySm9Qa1E2VldNc08wMzVVNkJwUnVHek1ydEcwVS0tejc2bWkwQlRKb3p3eEZRc2VRX0dBcXRtZEhJRTA?oc=5","date":"2025-11-19","type":"deal","source":"PR Newswire","summary":"Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc - PR Newswire","headline":"Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNZmhicEppeTc3dFl0WURRMW5MVlAxSTJZZ3VWN0NUS052SFhSWTJmcDdHQkFWVFpoUWhKU19YQk5kRUdmNDdheHZ2MmxHQkc1djlBWFFVdDUxME41YWxUN0lHMjdOdXJvQXZ5WGtxZE5qT3dVNzhMQjlDbmVFZVptZHN1Q2lXNnZReEZJVF85bnBlSHk5dmt5TzNxREh3UFRxaEFSVVdIVXFsSm5rQkR1QnhrZnBZQ2gy?oc=5","date":"2025-11-19","type":"pipeline","source":"The Business Journals","summary":"Avadel Pharmaceuticals agrees to sweetened $2.37B takeover bid from Alkermes amid bidding war - The Business Journals","headline":"Avadel Pharmaceuticals agrees to sweetened $2.37B takeover bid from Alkermes amid bidding war","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-31","type":"pipeline","source":"simplywall.st","summary":"Alkermes plc Just Recorded A 62% EPS Beat: Here's What Analysts Are Forecasting Next - simplywall.st","headline":"Alkermes plc Just Recorded A 62% EPS Beat: Here's What Analysts Are Forecasting Next","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNNmNGclBYbWxwQVhhVHEtcjJJQ21pTV9QaWNuSFBnWHBXMVZlWmlpOXZMc3JvNWlNampDSmViUGMyZ0VlTEdNMGpET3ZsMC1id2s1ckdDZ20wdFBMNHd4N09hbTFBV25WMUlIMTR3b1BoUUNicVVZVkhzQW1nSEdKQ19rWGlTY0NCWU9Kelg4dzN6ZTFHNmZ1RUF4dzcxYTZBS2QyTkFzYlpCQjNY?oc=5","date":"2025-10-22","type":"pipeline","source":"Seeking Alpha","summary":"Alkermes plc (ALKS) Avadel Pharmaceuticals plc - M&A Call - Slideshow (NASDAQ:ALKS) 2025-10-22 - Seeking Alpha","headline":"Alkermes plc (ALKS) Avadel Pharmaceuticals plc - M&A Call - Slideshow (NASDAQ:ALKS) 2025-10-22","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxOdF9pcmtJV3hVUldFZ1d1VUtJNDVMUnVoWVZYQlV2cGVvVXNkemRQWGtVbGdCQUxSclBUam96OU5yWHFPVmFDcDlXVzJfa3BWNmloVVlxN2NnMUsxZWxvcGJEbzBjUHM0Mm1LRDd4akFGRHB1Z25vU1NPRXhRX1JlVHF2ZkpqYjFPMUxXNExfRWF3YWs3cnlqT21JZnhPRG5zWnNmdUs5VFlUWE5GZWMzcTR1XzViVEhLbUdZeDc2SnM1MWtN?oc=5","date":"2025-10-22","type":"deal","source":"PR Newswire","summary":"Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc - PR Newswire","headline":"Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNeG9WUGhtelE0MjhNYU9zeUpQYm1VYXlGc29GRnhqckl4WmZMWHA0N2otWTN0eV8yUjVZTVZDUFZ6TmpXNnB6MEdRMXBTVTB1eTczM01Jd0VNcUl1RXBkUnAtU19IeW5RY1ZIMUE0VllyUlNuT2Z5ZjhmT2wyc2tVSVh3MXJ0QjIweUJBVTVzTGoxSmwzZUcwV2NUcjVQeERfYklXSWtzS2JZOGZiaU55V2x5aEctVVVFNEE?oc=5","date":"2025-10-20","type":"pipeline","source":"Stocktwits","summary":"Avadel Stock Rises After Acquisition Offer By Alkermes - Stocktwits","headline":"Avadel Stock Rises After Acquisition Offer By Alkermes","sentiment":"neutral"}],"patents":[{"drugName":"VIVITROL","drugSlug":"naltrexone","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":444400000},{"drugName":"Aristada","drugSlug":"aripiprazole-lauroxil","patentNumber":"10226458","type":"Method of Use","expiryDate":"2032-03-19","territory":"US","annualRevenue":500000000,"genericFilings":[]},{"drugName":"Aristada","drugSlug":"aripiprazole-lauroxil","patentNumber":"9034867","type":"Formulation","expiryDate":"2032-11-07","territory":"US","annualRevenue":500000000,"genericFilings":[]},{"drugName":"Aristada","drugSlug":"aripiprazole-lauroxil","patentNumber":"12311027","type":"Formulation","expiryDate":"2033-09-19","territory":"US","annualRevenue":500000000,"genericFilings":[]},{"drugName":"Aristada","drugSlug":"aripiprazole-lauroxil","patentNumber":"9193685","type":"Formulation","expiryDate":"2033-10-24","territory":"US","annualRevenue":500000000,"genericFilings":[]},{"drugName":"Aristada","drugSlug":"aripiprazole-lauroxil","patentNumber":"11097006","type":"Formulation","expiryDate":"2033-10-24","territory":"US","annualRevenue":500000000,"genericFilings":[]},{"drugName":"Aristada","drugSlug":"aripiprazole-lauroxil","patentNumber":"11969469","type":"Formulation","expiryDate":"2033-10-24","territory":"US","annualRevenue":500000000,"genericFilings":[]},{"drugName":"CARIPrazine","drugSlug":"cariprazine","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":143800000},{"drugName":"Aristada","drugSlug":"aripiprazole-lauroxil","patentNumber":"9452131","type":"Method of Use","expiryDate":"2035-03-19","territory":"US","annualRevenue":500000000,"genericFilings":[]},{"drugName":"Aristada","drugSlug":"aripiprazole-lauroxil","patentNumber":"10238651","type":"Method of Use","expiryDate":"2035-03-19","territory":"US","annualRevenue":500000000,"genericFilings":[]},{"drugName":"Aristada","drugSlug":"aripiprazole-lauroxil","patentNumber":"10813928","type":"Method of Use","expiryDate":"2035-03-19","territory":"US","annualRevenue":500000000,"genericFilings":[]},{"drugName":"Aristada","drugSlug":"aripiprazole-lauroxil","patentNumber":"11406632","type":"Method of Use","expiryDate":"2035-03-19","territory":"US","annualRevenue":500000000,"genericFilings":[]},{"drugName":"Aristada","drugSlug":"aripiprazole-lauroxil","patentNumber":"9526726","type":"Formulation","expiryDate":"2035-03-19","territory":"US","annualRevenue":500000000,"genericFilings":[]}],"drugCount":22,"phaseCounts":{"marketed":6,"phase_1":3,"phase_3":12,"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Johnson & Johnson","Pfizer","Eli Lilly and Company"],"therapeuticFocus":["Central Nervous System (CNS) Disorders","Opioid Use Disorder"],"financials":{"source":"sec_edgar","revenue":1475899000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":1475899000,"period":"2025-12-31"},{"value":1557632000,"period":"2024-12-31"},{"value":1557632000,"period":"2024-12-31"},{"value":1663405000,"period":"2023-12-31"},{"value":1663405000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":323964000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":241664000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":2486993000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":34.18,"previousClose":33.02,"fiftyTwoWeekHigh":36.48,"fiftyTwoWeekLow":25.17,"fiftyTwoWeekRange":"25.17 - 36.48","fiftyDayAverage":31.42,"twoHundredDayAverage":29.75,"beta":0.39,"enterpriseValue":4984564736,"forwardPE":17.1,"priceToBook":3.11,"priceToSales":3.86,"enterpriseToRevenue":3.38,"enterpriseToEbitda":17.73,"pegRatio":0,"ebitda":281120992,"ebitdaMargin":19,"freeCashflow":-363090624,"operatingCashflow":520753984,"totalDebt":69999000,"debtToEquity":3.8,"currentRatio":3.55,"returnOnAssets":7,"returnOnEquity":14.7,"analystRating":"1.5 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":17,"targetMeanPrice":43.71,"targetHighPrice":58,"targetLowPrice":30,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":1.6,"institutionHeldPercent":110.2,"sharesOutstanding":166252718,"floatShares":154044533,"sharesShort":20600815,"shortRatio":9.99,"shortPercentOfFloat":12.4,"epsTrailing":1.39,"epsForward":1.99,"revenuePerShare":8.96,"bookValue":10.99,"officers":[{"age":63,"name":"Mr. Richard F. Pops","title":"Chairman & CEO"},{"age":52,"name":"Mr. Blair C. Jackson","title":"Executive VP, Chief Risk Officer & COO"},{"age":53,"name":"Mr. David Joseph Gaffin J.D.","title":"Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary"},{"age":56,"name":"Dr. Craig C. Hopkinson M.D.","title":"Executive VP of Research & Development and Chief Medical Officer"},{"age":55,"name":"Mr. Christian Todd Nichols","title":"Senior VP & Chief Commercial Officer"},{"age":51,"name":"Mr. Joshua  Reed M.B.A.","title":"Senior VP & CFO"},{"age":50,"name":"Mr. Samuel J. Parisi","title":"Interim Principal Accounting Officer & VP of Finance"},{"age":null,"name":"Mr. Thomas  Harvey","title":"Chief Information Officer & Senior VP of IT"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"http://investor.alkermes.com/phoenix.zhtml?c=92211&p=irol-irhome","website":"https://www.alkermes.com","phone":"353 1 772 8000"}}